Clinical Trials Browser

Phase 2/3 × INDUSTRY × Breast Neoplasms × Clear all

NCT06062810 2026-04-09

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07294508 2026-03-20

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 3 FDA

Breast Neoplasms

NCT05860465 2026-01-14

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05744687 2025-08-17

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT03354611 2023-03-16

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Phase 2/3 Terminated

Breast Neoplasms

NCT01881230 2019-02-21

tnAcity

Phase 2/3 Completed

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00535418 2017-09-05

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Phase 2/3 Completed

Breast Neoplasms

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms

NCT01572727 2017-03-09

BELLE-4

Phase 2/3 Completed

416 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT02213744 2017-01-06

HERMIONE

Phase 2/3 Terminated

Breast Neoplasms

NCT01433562 2013-05-13

Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Phase 2/3 Completed

Breast Neoplasms

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Phase 2/3 Completed

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00333047 2009-11-19

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Phase 2/3 Completed

Breast Neoplasms